The aim of the present study was to determine if the MM-MSC phenotype is associated to a higher mitochondrial trafficking and assess whether mitochondria uptake is regulated by CXCL12/CXCR4 axis in order to provide new potential treatment strategy to overcome chemoresistance and improve clinical outcome and quality of life of MM patients. This evidence concerns the gene CXCL12 and Miyoshi myopathy.